桂枝茯苓胶囊辅助治疗子宫内膜异位症效果观察

发布时间：2018-01-20 13:53

本文关键词： 子宫内膜异位症桂枝茯苓胶囊 CA 高敏C反应蛋白血管内皮生长因子　出处：《山东医药》2015年40期 　论文类型：期刊论文

【摘要】：目的探讨桂枝茯苓胶囊辅助治疗子宫内膜异位症(EMs)的效果及其可能的作用机制。方法选择EMs患者102例,随机分为观察组、对照组各51例。两组均先行腹腔镜手术,术后口服米非司酮12.5 mg、1次/晚;观察组在此基础上餐后口服桂枝茯苓胶囊3粒/次、3次/d。两组均治疗6个月。比较两组总有效率,治疗前后血清CA125、高敏C反应蛋白(hs-CRP)和血管内皮生长因子(VEGF)水平及不良反应发生率。结果观察组总有效率为96.1%(49/51),对照组为84.3%(43/51),两组比较P0.05。两组治疗后血清CA125、hs-CRP和VEGF水平均降低,且观察组治疗后低于对照组(P均0.05)。观察组不良反应发生率为7.8%(4/51),对照组为29.4%(15/51),两组比较P0.05。结论桂枝茯苓胶囊辅助治疗EMs安全、有效,其作用机制可能与减轻炎症反应、减少异位血管生成有关。
[Abstract]:Objective to investigate the effect and possible mechanism of Guizhi Fuling capsule in the treatment of endometriosis. Methods 102 patients with EMs were randomly divided into two groups. In the control group, 51 cases in each group were treated with laparoscopy. After operation, the patients were treated with Mifepristone 12.5 mg / night. On this basis, the observation group took Guizhi Fuling capsule 3 tablets / 3 times per day after meal. The two groups were treated for 6 months. The total effective rate of the two groups and serum CA125 before and after treatment were compared. The levels of Gao Min C-reactive protein (hs-CRP) and vascular endothelial growth factor (VEGF) and the incidence of adverse reactions. Results the total effective rate of the observation group was 96.1g / 49 / 51). The control group was 84.3% / 51g, compared with P0.05.The levels of serum CA125hs-CRP and VEGF were decreased after treatment in both groups. The incidence of adverse reactions in the observation group was 7. 8% or 4 / 51%, and in the control group was 29. 4% / 51% (P < 0. 05). Conclusion Guizhi Fuling capsule is safe and effective in the treatment of EMs, and its mechanism may be related to reducing inflammatory reaction and reducing ectopic angiogenesis.
【作者单位】：肥城市人民医院;
【分类号】：R711.71
【正文快照】： 子宫内膜异位症(EMs)临床常见,多发于育龄妇女,临床表现主要为盆腔疼痛和不孕等[1]。目前治疗EMs的主要方法是腹腔镜手术,但术后易复发,且需服用激素类药物,不良反应较多。中医认为,EMs属于痛经、月经不调、不孕、ve瘕等疾病范畴,病机多为血瘀,具体证型又有寒、热、虚、实之别

【参考文献】